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Abstract We tested the hypothesis that homocysteine
levels are higher in blood of schizophrenic subjects on
clozapine monotherapy than in healthy controls and they
correlate with anthropometric measurements, laboratory
tests and results of bioimpedance analysis of body com-
position. Data for 24 subjects with schizophrenia treated
with clozapine and 24 age- and sex-matched healthy vol-
unteers was analyzed. Regarding the whole group, homo-
cysteine levels were significantly higher in men (17.0 ±
3.4 vs. 12.1 ± 4.0 lmol/L, p = 0.009). Homocysteine
levels correlated with waist circumference (R = 0.58,
p = 0.003), waist-to-hip ratio (R = 0.57, p = 0.003),
basal metabolic rate (R = 0.48, p = 0.01), lean body mass
[kg] (R = 0.53, p = 0.008), body water [L] (R = 0.53,
p = 0.008) and triglycerides (R = 0.57, p = 0.003). There
were no significant differences of homocysteine levels for
impaired fasting glucose, abdominal obesity, obesity/
overweight, and dyslipidemia. Homocysteine levels did not
correlate with age, treatment duration, clozapine dose,
weight, body mass index, abdominal circumference, blood
pressure, total body fat, cholesterol, high density lipopro-
teins, low density lipoproteins, uric acid, calcium, glucose,
insulin, homoeostasis model assessment of insulin resis-
tance 1, and homoeostasis model assessment of insulin
resistance 2. We did not find significant differences in
blood homocysteine levels between subjects with schizo-
phrenia and controls. Association with waist circumference
may support homocysteine role as an important cardio-
vascular risk factor. Association with lean weight may
explain why men have higher levels of homocysteine than
women.
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Abbreviations
CVD Cardio-vascular disease
BIA Body impedance analysis
BMI Body mass index
WHR Waist-to-hip ratio
SBP Systolic blood pressure
DBP Diastolic blood pressure
TC Total cholesterol
HDL High density lipoproteins
LDL Low density lipoproteins
TGA Triglycerides
FPG Fasting plasma glucose
HOMA1-IR Homoeostasis model assessment of insulin
resistance 1
HOMA2-IR Homoeostasis model assessment of insulin
resistance 2
Introduction
Homocysteine is an amino-acid produced during demeth-
ylation of methionine. High levels of homocysteine in
blood are associated with increased risk of cardiovascular
disease (CVD) [1]. Patients with schizophrenia may have
increased levels of homocysteine [2] and this may add to
increased CVD risk due to treatment with antipsychotics
[3]. Homocysteine concentration is inversely related to the
intake and plasma levels of folate [4], while folate defi-
ciency is common in schizophrenic patients [5]. As it was
A. Wysokin´ski (&)  I. Kłoszewska
Department of Old Age Psychiatry and Psychotic Disorders,




Neurochem Res (2013) 38:2056–2062
DOI 10.1007/s11064-013-1113-1
shown by Lee et al. [6], raised homocysteine levels may also
result from the 677TT genotype of methylenetetrahy-
drofolate reductase (MTHFR), enzyme that catalyzes the
conversion of 5,10-methylenetetrahydrofolate to 5-methyl-
tetrahydrofolate, a cosubstrate for homocysteine remethyla-
tion to methionine. Homocysteine may trigger neuronal
apoptosis [7], promote oxidative stress [8] and induce
neurotoxicity via the N-methyl-D-aspartate (NMDA)
receptor [9]. It may also increase the risk of tardive dyski-
nesia in schizophrenia patients [10]. Levine et al. [11]
showed that simple interventions aimed at reducing homo-
cysteine levels (supplementation with B vitamins) may
improve clinical and cognitive symptoms in chronic
schizophrenic patients with hyperhomocysteinemia.
After more than 50 years since it has been discovered,
clozapine remains an ultimate option for patients with
treatment resistant schizophrenia [12]. Its high efficacy is
combined with very low level of extrapyramidal symptoms
and ability to ameliorate tardive dyskinesia. However,
treatment with clozapine is associated with increased risk
of fatal agranulocytosis and has also a very detrimental
effect on metabolic profile [13], which may contribute to
dramatically increased mortality of schizophrenia patients
[14]. Clozapine has a very distinctive pharmacological
profile, which probably underlies its efficacy and side-
effects [15]. Apart from its affinity to various receptors for
monoamine neurotransmitters, its has several unique
properties, some of them are linked to actions induced by
homocysteine. Clozapine blocks neurotoxicity in the rat
cortex induced by noncompetitive NMDA receptor antag-
onist dizocilpine [16]. It may also provide some degree of
neuroprotection, specifically against oxidative stress [17].
Using an animal model, Moller et al. [18] showed that
clozapine may reverse cortico-striatal oxidative stress.
However, it was also demonstrated by Fehsel et al. [19]
that clozapine induces oxidative stress in neutrophils,
which may trigger agranulocystosis.
Aims of the Study
The present study was undertaken with the purpose to
determine whether subjects on monotherapy with clozapine
have higher levels of blood homocysteine comparing to
healthy control. In order to provide more accurate mea-
surements, biochemical and anthropometric measurements
were combined with body composition determined using
bioelectric impedance analysis (BIA), which provides
accurate measurements of body fat, lean mass and body
water [20]. To the best of our knowledge, this is the first
study to investigate such combination of these parameters
in subjects with schizophrenia.
Materials and Methods
Data for 24 European Caucasian adult patients with para-
noid schizophrenia (295.30, according to DSM-IV) was
included into the study. These subjects were on clozapine
monotherapy for at least 2 months prior the assessments.
Control group was 24 healthy subjects and was gender- and
age-matched with patients in the clozapine group. All
patients and volunteers included in the study have been
informed about aims and methods of the study and
expressed their written informed consent for participation
in this study. The study protocol was approved by the local
Bioethics Committee. There was no financial involvement
from the industry.
Laboratory Tests
The blood samples for the chemistry panel were collected
between 7 am and 8 am, after ensuring at least 8 h of over-
night fasting. The samples were immediately transferred to
the central laboratory where they were analyzed. Glucose,
lipids, calcium and uric acid levels were measured using a
Dirui CS-400 analyzer (Dirui, China). Homocysteine
chemiluminescence assessments were performed using an
Immulite 2000 analyzer (Siemens, Germany), insulin
immunochemistry assessments were performed using a
Cobas E411 analyzer (Roche Diagnostics, Switzerland) and
albumin levels were assessed using a Cobas Integra 800
analyzer (Roche Diagnostics, Switzerland).
Impaired fasting glucose was defined as fasting plasma
glucose C100 mg/dL. BMI \25 kg/m2, 25–30 kg/m2 and
C30 kg/m2 were defined as normal weight, overweight and
obesity, respectively. Raised triglycerides (TGA) level
C150 mg/dL and/or total cholesterol (TC) C200 mg/dL
and/or reduced HDL cholesterol level\40 mg/dL for men
and \50 mg/dL for women and/or raised LDL cholesterol
level C135 mg/dL were interpreted as dyslipidemia. Cor-
rected calcium was calculated using the formula: corrected
calcium (mg/dL) = measured total calcium (mg/dL) ? 0.8
(4.0 - serum albumin [g/dL]). Insulin resistance was
estimated from fasting glucose and insulin results by
homeostasis model assessment, using the formula:
HOMA1-IR = (fasting plasma glucose [mg/dL] 9 insulin
[mU/L])/405. HOMA2-IR index was calculated using a
calculator downloaded from http://www.dtu.ox.ac.uk.
Anthropometric Assessment
Height was measured with a wall-mounted height measure
to the nearest 0.5 cm. Weight was measured with a spring
balance that was kept on a firm horizontal surface. Subjects
wore light clothing, stood upright without shoes and weight
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was recorded to the nearest 0.5 kg. Body mass index (BMI)
was calculated as body weight in kilogram divided by the
height in meter squared (kg/m2). Waist, abdominal and hip
circumference was measured using a non-stretchable fibre
measuring tape.
Body Composition Assessment
Body composition was measured using a Maltron BF-906
body fat analyser (Maltron, UK), single frequency bio-
electrical impedance analyser to determine resistance and
reactance at 50 Hz. Standard operating conditions were
observed by a trained operator including preparation of the
participant, electrode placement and operation. The mea-
surement using BIA was taken immediately prior to
anthropometry measurements with participants lying
supine, in a rested state.
Statistical Methods
Statistical procedures were performed with STATA 12.1
for OS X (StataCorp, College Station, Texas, USA). Sim-
ple descriptive statistics (means and standard deviations,
median (Q2), 25 and 75 % quartiles (Q1 and Q3)) were
generated for all continuous variables. For discrete vari-
ables number of patients and percentages are given. Inter-
group differences were analyzed using Mann–Whitney
U test. The difference between proportions was analyzed
by Fisher’s exact test. Associations were tested by Spear-
man’s correlation coefficient. The significant level was set
at p \ 0.05.
Results
For group of patients treated with clozapine the mean age
was 38.8 ± 12.6 [Q1 = 28.0, Q2 = 38.5, Q3 = 47.5] and
39.9 ± 12.3 [Q1 = 30.5, Q2 = 36.0, Q3 = 52.0] for the
control group; there was no significant difference between
the groups in age (p = 0.62). In both groups there were 12
men, i.e. half of group, and 12 women. In the clozapine
group 12 (half of group) subjects smoked cigarettes and 8
in the control group (p = 0.38). The mean duration of
monotherapy with clozapine was 131.8 ± 114.3 [Q1 =
8.5, Q2 = 33.0, Q3 = 84.0] months and mean clozapine
dose was 341.1 ± 148.6 [Q1 = 237.5, Q2 = 300.0,
Q3 = 425.0] mg/day. Detailed results for anthropometric
measurements and laboratory tests are shown in Table 1.
We have found no inter-group differences for body com-
position analysis. Detailed results for BIA analysis are
shown in Table 2. Lean body mass was higher in men
in the whole study sample (60.1 ± 6.4 [Q1 = 53.8,
Q2 = 59.7, Q3 = 63.6] vs. 43.8 ± 5.4 kg [Q1 = 41.3,
Q2 = 43.9, Q3 = 46.4], z = -5.74, p \ 0.001) and in the
clozapine group (59.6 ± 5.7 [Q1 = 55.3, Q2 = 59.7,
Q3 = 61.4] vs. 45.3 ± 7.0 kg [Q1 = 42.5, Q2 = 46.4,
Q3 = 49.1], z = -3.93, p \ 0.001). Similarly, basal
metabolic rate was higher in men in the whole study
sample (1,707.7 ± 182.3 [Q1 = 1,567.0, Q2 = 1,731.0,
Q3 = 1,837.0] vs. 1,337.3 ± 138.4 [Q1 = 1,229.5, Q2 =
1,380.5, Q3 = 1,389.0] kg, z = -5.32, p \ 0.001) and in
the clozapine group (1,701.2 ± 138.2 [Q1 = 1,582.0,
Q2 = 1,722.5, Q3 = 1,790.0] vs. 1,362.7 ± 173.0 [Q1 =
1,281.5, Q2 = 1,388.5, Q3 = 1,465.0] kg, z = -3.87,
p \ 0.001).
In the clozapine group fasting homocysteine levels cor-
related with waist circumference (R = 0.58, p = 0.003),
waist-to-hip ratio (R = 0.57, p = 0.003), basal metabolic
rate (R = 0.48, p = 0.01), lean body mass [kg] (R = 0.53,
p = 0.008), body water [L] (R = 0.53, p = 0.008) and
TGA (R = 0.57, p = 0.003). Fasting serum homocyste-
ine concentration did not correlate with age (R = 0.24,
p = 0.26), duration of clozapine treatment (R\ 0.01,
p = 0.98), clozapine dose (R = 0.02, p = 0.91), weight
(R = 0.38, p = 0.07), BMI (R = 0.25, p = 0.23), abdom-
inal circumference (R = 0.35, p = 0.09), systolic blood
pressure (R = 0.06, p = 0.77), diastolic blood pressure
(R = 0.09, p = 0.66), total body fat [kg] (R = 0.13,
p = 0.56), TC (R = 0.38, p = 0.7), HDL (R = -0.38,
p = 0.06), LDL (R = 0.39, p = 0.06), uric acid (R = 0.29,
p = 0.17), corrected calcium (R = -0.12, p = 0.57), glu-
cose (R = -0.07, p = 0.76), insulin (R = 0.04, p = 0.83),
HOMA1-IR (R = -0.16, p = 0.45), HOMA2-IR (R =
-0.01, p = 0.97).
The normal clinical laboratory range for homocysteine
was 5.0–12.0 lmol/L. There was no difference of fasting
homocysteine concentrations between clozapine and control
group (14.5 ± 4.4 [Q1 = 11.3, Q2 = 15.5, Q3 =
17.7] vs. 13.6 ± 5.0 [Q1 = 10.2, Q2 = 13.5, Q3 =
16.5] lmol/L, p = 0.48). In the clozapine group homocys-
teine levels were significantly higher in men than in women
(17.0 ± 3.4 [Q1 = 15.4, Q2 = 17.2, Q3 = 18.5] vs.
12.1 ± 4.0 [Q1 = 8.1, Q2 = 11.9, Q3 = 15.5] lmol/L,
z = -2.63, p = 0.009). The difference between men and
women was also significant for the whole study population
(16.5 ± 3.4 [Q1 = 14.0, Q2 = 17.0, Q3 = 18.2] vs.
11.6 ± 4.6 [Q1 = 8.1, Q2 = 11.8, Q3 = 14.4] lmol/L,
z = -3.69, p \ 0.001). Blood homocysteine levels were not
significantly different between men with schizophrenia and
healthy men (17.0 ± 3.4 [Q1 = 15.4, Q2 =
17.2, Q3 = 18.5] vs. 16.0 ± 3.5 [Q1 = 11.8, Q2 = 13.7,
Q3 = 14.4] lmol/L, p = 0.4) and between women with
schizophrenia and healthy women (12.1 ± 4.0 [Q1 = 8.1,
Q2 = 11.9, Q3 = 15.5] vs. 11.2 ± 5.2 [Q1 = 8.0, Q2 =
10.6, Q3 = 13.2] lmol/L, p = 0.6). In the clozapine group
there were no significant differences between smokers and
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non-smokers (13.6 ± 4.8 [Q1 = 9.0, Q2 = 14.2, Q3 =
16.7] vs. 15.5 ± 3.9 [Q1 = 11.9, Q2 = 16.2, Q3 = 18.5]
lmol/L, p = 0.21), subjects with normal and impaired fasting
glucose (14.9 ± 4.6 [Q1 = 11.5, Q2 = 15.3, Q3 = 16.2] vs.
14.1 ± 4.53 [Q1 = 8.2, Q2 = 16.8, Q3 = 18.2] lmol/L,
p = 0.98), subjects with total body fat lower and higher than
target maximum based on BIA (14.4 ± 4.3 [Q1 = 10.7,
Q2 = 15.7, Q3 = 17.7] vs. 15.2 ± 5.4 [Q1 = 11.4,
Q2 = 13.4, Q3 = 19.0] lmol/L, p = 0.93), subjects with
BMI \25 and C25 kg/m2 (13.6 ± 5.2 [Q1 = 11.5,
Q2 = 12.4, Q3 = 15.2] vs. 14.8 ± 4.2 [Q1 = 11.2,
Q2 = 15.9, Q3 = 18.2] lmol/L, p = 0.93), without
abdominal obesity and with abdominal obesity (15.4 ± 4.2
[Q1 = 11.6, Q2 = 15.7, Q3 = 18.2] vs. 12.4 ± 4.3
[Q1 = 8.2, Q2 = 12.2, Q3 = 16.2] lmol/L, p = 0.19),
without and with dyslipidemia (12.6 ± 5.0 [Q1 = 8.2,
Q2 = 11.5, Q3 = 15.3] vs. 15.7 ± 3.7 [Q1 =
13.3, Q2 = 16.2, Q3 = 18.3] lmol/L, p = 0.08). No
such differences were also found for the whole study
group.
Table 1 Results of
anthropometric measurements
and laboratory tests
Data given as mean ± standard
deviation (25 % quartile,
median, 75 % quartile)
BMI body mass index, WHR
waist-to-hip ratio, SBP systolic
blood pressure, DBP diastolic
blood pressure, TC total
cholesterol, HDL high density
lipoproteins, LDL low density
lipoproteins, TGA triglycerides,
FPG fasting plasma glucose,
HOMA1-IR homoeostasis model
assessment of insulin resistance
1, HOMA2-IR homoeostasis
model assessment of insulin
resistance 2
Clozapine (n = 24) Control (n = 24) p
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Discussion
Contrary to other observations [2], we did not find that
subjects with schizophrenia on clozapine monotherapy had
higher fasting homocysteine levels comparing to age- and
sex-matched healthy controls. However, using two-sample
mean-comparison calculator we have found that homo-
cysteine levels in men were not significantly different than
reported by Levine et al. (16.3 ± 11.8 lmol/L; p = 0.42)
[21] and significantly higher then reported by Henderson
et al. (7.69 ± 1.42 lmol/L; t51 = -14.06, p \ 0.001) [22].
It should be noted that subjects in the study of Henderson
et al. had schizophrenia or schizoaffective disorder and
were taking clozapine, risperidone or olanzapine as
monotherapy. No details for antipsychotic treatment were
given by Levine et al. in their paper. Therefore, we may
assume that homocysteine levels in our patients were rel-
atively high, particularly in men. Considering atherogenic
properties of homocysteine, this is important since in many
cases treatment with clozapine is associated with metabolic
side-effects significantly increasing the risk of cardiovas-
cular events. We have confirmed previous observations that
fasting homocysteine levels are higher in men than in
women, both in the clozapine group, as well as in the whole
study population. It was previously reported by Sanchez-
Margalet et al. [23] that obese subjects have higher levels
of homocysteine. We have found no such associations for
abdominal obesity, general obesity (determined using
BMI-based cut-off values) and in subjects with total body
fat higher than target maximum calculated using BIA.
Homocysteine levels were positively correlated with
waist circumference and WHR, but not with BMI. Con-
sidering the association between hyperhomocysteinemia
and raised risk of CVD, this observation is consistent with
previous reports that WHR is the best predictor of CVD
risk, premature death, stroke, non-insulin-dependent dia-
betes mellitus and female carcinomas [24], while BMI is
negatively correlated to cardiovascular disease, premature
death, and stroke, but positively to diabetes [25]. Lin et al.
[26] has shown that in male patients with coronary artery
disease homocysteine levels are strongly associated with
WHR, but not with BMI. Association between homocys-
teine and TGA blood levels also indicates a potential
impact of homocysteine on CVD risk.
Table 2 Results of body
composition analysis
Data given as mean ± standard
deviation (25 % quartile,
median, 75 % quartile)
Clozapine (n = 24) Control (n = 24) P
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In our study fasting homocysteine levels were positively
correlated with lean body mass and body water. Similar
results were previously reported for healthy subjects by
Battezzati et al. [27]. Several mechanisms explaining this
association were proposed (e.g. amount of fat-free mass
determines creatine synthesis, which is the single quanti-
tatively most important biological reaction requiring
methyl groups from methionine to produce homocysteine
or the fact that the level of creatinine, whose production is
related to fat-free mass, is positively related to the homo-
cysteine concentration). We have found that both in the
clozapine group and in the whole study population men had
higher amount of lean body mass, which may explain why
homocysteine levels are higher in men. The same reasoning
could be used to explain observed association between
homocysteine levels and basal metabolic rate, since it was
also significantly higher in men than in women.
Finally, apart from TGA, we have found no other
associations of homocysteine blood levels with any bio-
chemical variable analyzed. Contrary to Henderson et al.
[22], we also have found no differences between subjects
with normal and impaired fasting blood glucose. However,
we were not able to stratify our study sample by folate
intake or levels, which was done by these authors. Since
they found that folate effects may differ depending on
fasting glucose status, we cannon exclude that different
folate levels in our subjects could have resulted in the
absence of such association. Our observations are similar to
previously reported by Abbasi et al. [28], who found no
relationship between insulin resistance and plasma homo-
cysteine concentrations in a group of healthy volunteers.
Conclusions
There was no significant difference in blood homocysteine
levels between patients wit schizophrenia treated with
clozapine and mentally healthy controls. Men with
schizophrenia taking clozapine had a significantly higher
homocysteine levels than women. Homocysteine levels
were positively correlated with waist circumference, WHR,
TGA levels, basal metabolic rate, lean weight and body
water.
Low number of study subjects limited the probability of
finding inter-group differences due to lack of statistical
power. Due to the cross-sectional study design causal
relationships cannot be established and effect of previous
antipsychotic treatment cannot be excluded. Dual-energy
X-ray absorptiometry (DXA) could be used to measure
body composition and percentage of fat more accurately.
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